Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
If your doctor can document either of these conditions, your path to coverage becomes significantly clearer
NAD IV therapy is not a direct weight-loss solution, but it can support metabolism, increase energy, and improve exercise performance
The regulatory direction is clear
As part of the prior authorization process for Bridge, prescribing clinicians will need to attest that the GLP-1 prescription is for weight reduction and weight management and that beneficiaries meet the clinical criteria and do not have a diagnosis of type 2 diabetes, OSA, or MASH that would make them eligible for GLP-1 coverage under Part D
US$ 28.87
US$ 25.01
US$ 28.83
US$ 23.95
US$ 25.19
US$ 27.23
US$ 28.45
